Bank cuts Bavarian Nordic's price target 30% after shelved RSV vaccine
Danish bank Danske Bank has cut almost 30% of its share price target for Bavarian Nordic after the vaccine manufacturer last weekend dropped its development program for a vaccine against RSV after a failed phase III study.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Bavarian Nordic CEO says R&D efforts won't be discontinued
For subscribers